Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Benzinga · 3d ago
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.